These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 23517836)

  • 21. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials.
    de Ribamar Costa J; Abizaid A; Bartorelli AL; Whitbourn R; Jepson N; Perin M; Steinwender C; Stuteville M; Ediebah D; Sudhir K; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1255-1262. PubMed ID: 27866134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies.
    Tarantini G; Masiero G; Barioli A; Paradies V; Vlachojannis G; Tellaroli P; Cortese B; di Palma G; Varricchio A; Ielasi A; Loi B; Steffenino G; Ueshima D; Mojoli M; Smits P
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):E115-E124. PubMed ID: 29513403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study.
    Farooq V; Gomez-Lara J; Brugaletta S; Gogas BD; Garcìa-Garcìa HM; Onuma Y; van Geuns RJ; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):880-8. PubMed ID: 22514149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial.
    Applegate R; Hermiller J; Williams J; Gordon P; Doostzadeh J; Cao S; Su X; Sudhir K; Lansky A; Simonton C; Stone G
    Catheter Cardiovasc Interv; 2010 Nov; 76(5):644-51. PubMed ID: 20506356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
    Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
    JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.
    Zeng Y; Cavalcante R; Tenekecioglu E; Suwannasom P; Sotomi Y; Collet C; Abdelghani M; Jonker H; Digne F; Horstkotte D; Zehender M; Indolfi C; Saia F; Fiorilli R; Chevalier B; Bolognese L; Goicolea J; Nie S; Onuma Y; Serruys PW;
    Int J Cardiovasc Imaging; 2017 Apr; 33(4):441-449. PubMed ID: 28012050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison.
    Kugler C; Markovic S; Rottbauer W; Wöhrle J
    Coron Artery Dis; 2017 Mar; 28(2):120-125. PubMed ID: 27845998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials.
    Bartorelli AL; Serruys PW; Miquel-Hébert K; Yu S; Pierson W; Stone GW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):60-6. PubMed ID: 20578194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioresorbable Scaffold for Treatment of Coronary Artery Lesions: Intravascular Ultrasound Results From the ABSORB Japan Trial.
    Okada K; Honda Y; Kitahara H; Otagiri K; Tanaka S; Hollak MB; Yock PG; Popma JJ; Kusano H; Cheong WF; Sudhir K; Fitzgerald PJ; Kimura T;
    JACC Cardiovasc Interv; 2018 Apr; 11(7):648-661. PubMed ID: 29622143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.